Incretin-based Therapies for Type 2 Diabetes

Area of Science:

• Endocrinology
• Pharmacology
• Metabolic Diseases

Background:

• Type 2 diabetes management is evolving with a focus on incretin hormones.
• Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are key incretins regulating glucose homeostasis.
• Dipeptidyl peptidase-4 (DPP-4) rapidly degrades incretins, limiting their therapeutic potential.

Purpose of the Study:

• To review the therapeutic strategies for type 2 diabetes targeting incretin hormones.
• To discuss the mechanisms of action and clinical efficacy of incretin mimetics and DPP-4 inhibitors.
• To explore the potential of incretin-based therapies in preserving beta cell mass.

Main Methods:

• Review of preclinical studies and clinical trials on incretin-based therapies.
• Analysis of the pharmacological actions of GLP-1, GIP, incretin mimetics, and DPP-4 inhibitors.
• Evaluation of clinical outcomes including glucose levels, A1C, and body weight.

Main Results:

• Injectable incretin mimetics reduce glucose levels, A1C, and promote weight loss.
• Oral DPP-4 inhibitors effectively lower glucose and A1C without significant weight change.
• Approved DPP-4 inhibitors include sitagliptin and vildagliptin, with others in development.

Conclusions:

• Incretin-based therapies, including incretin mimetics and DPP-4 inhibitors, offer effective strategies for type 2 diabetes management.
• These therapies improve glycemic control through various mechanisms, including enhanced insulin secretion and reduced glucagon levels.
• Further research is needed to confirm the beta cell protective effects of these agents in humans.